Table 1.
Shown are the morphology and doubling time for each SCLC line along with the patient prior treatment, response to treatment and Myc status.
| Cell Line | Morphology, Growth Properties | Site of Origin | Prior Radiation | Prior Chemo | Chemo Regimen | Response | Myc | Doubling Time (h) |
|---|---|---|---|---|---|---|---|---|
| NCI-H82 | epithelial, suspension, multi-cell aggregates | pleural effusion | Y | Y | CMC/VAP, VP16 | CR | cMYC | 25.5 ± 4.2 |
| NCI-H211 | suspension | bone marrow | Y | Y | CMC/VAP | PR | cMYC | 55.6 ± 6.5 |
| NCI-H446 | epithelial, mixed adherent & floaters | pleural effusion | N | Y | CMC/VAP | PR | cMYC | 41.0 ± 4.6 |
| NCI-H524 | suspension | lymph node | N | Y | CMC/VAP | PR | cMYC | 38.4 ± 0.9 |
| NCI-H1650 | epithelial, adherent | pleural effusion | N | N | AD, PL | PD | cMYC | 41.3 ± 3.3 |
| NCI-H2171 | floating clusters, suspension | pleural effusion | Y | Y | VP/PL | PR | cMYC | 48.6 ± 6.7 |
| NCI-H69 | suspension, multi-cell aggregates | pleural effusion | Y | Y | CMC/VAP, VP16/iFOS | CR | N-MYC | 51.1 ± 3.1 |
| NCI-H526 | epithelial, round clusters in suspension | bone marrow | N | N | CMC/VAP | PD | N-MYC | 35.2 ± 1.7 |
| NCI-H720 | suspension | atypical carcinoid | Unknown | Unknown | Unknown | Unknown | N-MYC | 72.4 ± 26.7 |
| NCI-H378 | epithelial, suspension, multi-cell aggregates | pleural effusion | Y | Y | CMC/VAP | PR | L-MYC | 92.8 ± 12.9 |
| NCI-H510 | epithelial,, mixed adherent & floaters | brain/adrenal | Y | Y | CMC/VAP | SD | L-MYC | 152.3 ± 40.6 |
| NCI-H889 | epithelial clusters in suspension | lymph node | N | N | VP/PL | PR | L-MYC | 61.1 ± 5.1 |
| NCI-H1963 | suspension | carcinoma | N | N | VP/PL | CR | LMYC | 43.6 ± 7.6 |
| NCI-H2107 | epithelial, clusters in suspension | bone marrow | N | N | VP/PL | PR | LMYC | 63.4 ± 8.4 |
| NCI-H128 | floating aggregates | pleural effusion | Y | Y | CMC/VAP | PR | unamp | 77.3 ± 16.9 |
| NCI-H146 | epithelial, suspension, multi-cell aggregates | bone marrow | N | Y | CMC/VAP | PR | unamp | 52.9 ± 11.9 |
| NCI-H187 | suspension | pleural effusion | N | N | CAPO, MTX | PR | unamp | 67.7± 13.6 |
| NCI-H196 | suspension | pleural effusion | Y | Y | CAPO, PCI | CR | unamp | 80.1 ± 8.4 |
| NCI-H345 | epithelial, suspension, multi-cell aggregates | bone marrow | Y | Y | CMC/VAP | CR | unamp | 65.3 ± 8.6 |
| NCI-H740 | suspension | lymph node | N | N | VP/PL | PR | unamp | 79.7 ± 9.9 |
| NCI-H841 | mixed adherent & floaters | lymph node | Y | Y | CMC/VAP | NR | unamp | 31.2 ± 3.6 |
| NCI-H865 | aggregate in suspension | pleural effusion | Y | Y | CMC/VAP | CR | unamp | 80.9 ± 6.8 |
| NCI-H1688 | epithelial, adherent | derived from liver met | N | N | VP/PL | PD | unamp | 82.7 ± 15.6 |
| NCI-H1930 | aggregate in suspension | lymph node | N | N | VP/PL | CR | unamp | 147.4 ± 22.3 |
CMC/VAP: cyclophosphamide, methotrexate; AD:adriamycin; PL: cis-platinum; iFOS: ifosfamide; VP/Pl: VP16, cis-platinum; CAPO: cyclophosphamide, Adriamycin, cis-platinum, vincristine; PCI: Prophylactic cranial irradiation; Response: CR: complete remission; PR: partial remission; PD: progressive disease; SD: stable disease; NR: No response